|1.||Bräutigam, Matthias: 15 articles (09/2013 - 01/2002)|
|2.||Stuetz, Anton: 12 articles (09/2008 - 10/2002)|
|3.||Eichenfield, Lawrence F: 11 articles (12/2015 - 04/2002)|
|4.||Paul, Carle: 11 articles (06/2015 - 07/2002)|
|5.||Fölster-Holst, Regina: 10 articles (06/2015 - 01/2002)|
|6.||Boguniewicz, Mark: 9 articles (12/2015 - 04/2002)|
|7.||Meurer, Michael: 9 articles (06/2012 - 01/2002)|
|8.||Prous, J R: 9 articles (09/2007 - 01/2003)|
|9.||Rabasseda, X: 9 articles (09/2007 - 01/2003)|
|10.||Luger, Thomas: 8 articles (06/2015 - 01/2003)|
|1.||Atopic Dermatitis (Atopic Eczema)
01/01/2006 - "Pimecrolimus cream 1% has proven to be well tolerated, safe, and highly effective in clinical studies in patients with atopic dermatitis."
10/01/2007 - "Pimecrolimus cream 1% has proven to be well-tolerated and effective in controlled clinical studies in patients with atopic dermatitis (AD). "
04/01/2006 - "The present study demonstrates that the good efficacy and tolerability of pimecrolimus ointment which had been shown in controlled trials: i) could also be demonstrated on a very large cohort of patients with atopic dermatitis when used in the outpatient setting, and ii) were paralleled by a significant improvement in the quality of life."
10/01/2005 - "In multiple clinical trials comprising more than 19,000 patients, pimecrolimus cream has been shown to be very effective in suppressing atopic dermatitis and to have an excellent safety profile. "
11/01/2004 - "Pimecrolimus cream 1% was well tolerated and effective in patients with mild to very severe atopic eczema, with rapid onset of action and no disease rebound after discontinuation."
|2.||Psoriasis (Pustulosis Palmaris et Plantaris)
03/01/2004 - "Short-term, Phase I/II and Phase II trials of pimecrolimus administered orally in psoriasis and AD have shown that this drug is highly effective in a dose-dependent manner in patients with these diseases and has high safety profile. "
10/01/2002 - "We conclude that pimecrolimus taken orally is highly effective in a concentration-dependent manner in patients with psoriasis and on a short-term basis it is well tolerated and this is confirmed by its pharmacogenomic profile. "
10/01/2002 - "Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated."
11/01/2004 - "Pimecrolimus cream 1% is an effective treatment for inverse psoriasis with a rapid onset of action, and is safe and well-tolerated."
03/01/2009 - "Pimecrolimus 1% cream is effective in the treatment of psoriasis in an infant."
11/01/2007 - "Significantly more pimecrolimus-treated patients than vehicle-treated patients achieved clearance of eyelid dermatitis (45% vs. 19%, respectively). "
11/01/2007 - "Pimecrolimus cream 1% is effective in patients with head and neck dermatitis intolerant of, or dependent on, TCS. "
01/01/2003 - "Twice daily topical treatment of moderate to severe chronic hand dermatitis with pimecrolimus cream 1% results in low pimecrolimus blood levels, is well tolerated, safe, and effective."
01/01/2003 - "Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. "
01/01/2004 - "Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis."
01/01/2007 - "Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients."
01/01/2007 - "Pimecrolimus cream 1% is effective in patients with asteatotic eczema."
01/01/2004 - "In the published studies on the efficacy of the topical immunomodulator pimecrolimus, different eczema scores were used, and the impact on morphological key signs of eczema was not analysed. "
01/01/2007 - "Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema."
01/01/2007 - "Randomised controlled trials of 1.0% topical pimecrolimus used twice daily compared against other topical comparators for treating eczema. "
01/01/2007 - "Pimecrolimus cream 1% improved pruritus within 48 hours in children and adolescents with mild to moderate AD and achieved complete resolution of pruritus in a significantly greater number of subjects in the pimecrolimus group versus the vehicle group by the end of the 7-day treatment period (P = .008)."
08/01/2010 - "Pruritus relief, however, was significantly greater in the pimecrolimus group."
01/01/2007 - "In the per-protocol (PP) population, median times to a 1 point or more improvement in pruritus score were 48 and 72 hours for pimecrolimus and vehicle groups, respectively (P = .038). "
01/01/2007 - "The objective of this study was to assess time to onset of pruritus improvement in a pediatric population treated with pimecrolimus cream 1%. "
01/01/2006 - "A single-centre, non-controlled, open-label study was designed to assess the efficacy of topical pimecrolimus in the treatment of chronic vulvar pruritus. "
|3.||Adrenal Cortex Hormones (Corticosteroids)
|7.||Clobetasol (Clobetasol Propionate)
|5.||Phototherapy (Light Therapy)